Roche awaits positive news from EPO (European Patent Office) on PCR (polymerase chain reaction) patents
This article was originally published in Clinica
Executive Summary
Roche says it has moved forward in its years-old battle to secure rights to its polymerase chain reaction (PCR) patents in various markets. Its two foundational patents have been subject to challenges in the US, and in Europe, where last week the European Patent Office's board of appeals signalled to Roche its intention to maintain the '184 and '362 patents, against a consortium of cross-industry companies from the healthcare and agriculture industries that had launched an opposition to the patents in 1995.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.